Raiders’ Hudson Young and Morgan Smithies apologise for Las Vegas altercation ahead of NRL opener
Tanaka sends Leeds five points clear in dramatic late win over Sheffield United
Uefa president Ceferin makes outspoken intervention on European politics
More than 200,000 Canadians sign petition to revoke Musk’s citizenship
‘You dream about such things’: Brit who discovered missing pharaoh’s tomb may have unearthed another
Market value drops by 6% on concerns that new lung cancer drug may not be as successful as hoped
Nearly £10bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.
Shares in the Anglo-Swedish pharmaceutical company fell by as much as 6% on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the biggest faller among FTSE 100 companies.
More Stories
I became absorbed in strangers’ fertility journeys online
Virologist Wendy Barclay: ‘Wild avian viruses are mixing up their genetics all the time. It’s like viral sex on steroids’
Microsoft unveils chip it says could bring quantum computing within years